SOLV
Solventum Corporation
Medical - Care Facilities
Market Cap$12.32B
5Y Perf.+2.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SOLV vs TMO
Revenue, margins, valuation, and 5-year total return — side by side.
TMO
Thermo Fisher Scientific Inc.
Medical - Diagnostics & Research
Market Cap$175.76B
5Y Perf.-18.6%
SOLV vs TMO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SOLV | TMO |
|---|---|---|
| Industry | Medical - Care Facilities | Medical - Diagnostics & Research |
| Market Cap | $12.32B | $175.76B |
| Revenue (TTM) | $8.26B | $45.20B |
| Net Income (TTM) | $1.43B | $6.86B |
| Gross Margin | 53.7% | 39.4% |
| Operating Margin | 25.5% | 17.8% |
| Forward P/E | 11.0x | 19.0x |
| Total Debt | $5.04B | $40.85B |
| Cash & Equiv. | $878M | $9.86B |
SOLV vs TMO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SOLV
TMO
| Stock | Mar 24 | May 26 | Return |
|---|---|---|---|
| Solventum Corporati… (SOLV) | 100 | 102.1 | +2.1% |
| Thermo Fisher Scien… (TMO) | 100 | 81.4 | -18.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SOLV vs TMO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SOLV leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Thermo Fisher Scientific Inc. is the stronger pick specifically for growth and revenue expansion and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
SOLV
Solventum Corporation
The Income Pick
SOLV carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.05
- Rev growth 0.9%, EPS growth 221.7%, 3Y rev CAGR 0.8%
- Lower volatility, beta 1.05, Low D/E 99.7%, current ratio 1.23x
Best for: income & stability and growth exposure
TMO
Thermo Fisher Scientific Inc.
The Long-Run Compounder
TMO is the clearest fit if your priority is long-term compounding.
- 229.1% 10Y total return vs SOLV's -11.2%
- 3.9% revenue growth vs SOLV's 0.9%
- 0.4% yield; 8-year raise streak; the other pay no meaningful dividend
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TMO | 3.9% revenue growth vs SOLV's 0.9% |
| Value | SOLV | Lower P/E (11.0x vs 19.0x) |
| Quality / Margins | SOLV | 17.3% margin vs TMO's 15.2% |
| Stability / Safety | SOLV | Beta 1.05 vs TMO's 1.10 |
| Dividends | TMO | 0.4% yield; 8-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | TMO | +16.6% vs SOLV's +8.5% |
| Efficiency (ROA) | SOLV | 10.0% ROA vs TMO's 6.4%, ROIC 16.9% vs 7.5% |
SOLV vs TMO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
SOLV vs TMO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSOLVLAGGINGTMO
TMOThermo Fisher Scienti…
0leads
SOLVSolventum Corporation
3leads
6 Total Categories
CATEGORYLEADERvs TMOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
SOLV5/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SOLV7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
SOLV2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — SOLV and TMO each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 5.5x SOLV's $8.3B. Profitability is closely matched — net margins range from 17.3% (SOLV) to 15.2% (TMO). On growth, TMO holds the edge at +6.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SOLVSolventum Corpora… | TMOThermo Fisher Sci… |
|---|---|---|
| RevenueTrailing 12 months | $8.3B | $45.2B |
| EBITDAEarnings before interest/tax | $2.9B | $10.5B |
| Net IncomeAfter-tax profit | $1.4B | $6.9B |
| Free Cash FlowCash after capex | -$203M | $6.7B |
| Gross MarginGross profit ÷ Revenue | +53.7% | +39.4% |
| Operating MarginEBIT ÷ Revenue | +25.5% | +17.8% |
| Net MarginNet income ÷ Revenue | +17.3% | +15.2% |
| FCF MarginFCF ÷ Revenue | -2.5% | +14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -3.0% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -91.0% | +11.3% |
Evenly matched — SOLV and TMO each lead in 3 of 6 comparable metrics.
Valuation Metrics
SOLV leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
At 8.0x trailing earnings, SOLV trades at a 70% valuation discount to TMO's 26.7x P/E. On an enterprise value basis, SOLV's 6.2x EV/EBITDA is more attractive than TMO's 19.0x.
| Metric | SOLVSolventum Corpora… | TMOThermo Fisher Sci… |
|---|---|---|
| Market CapShares × price | $12.3B | $175.8B |
| Enterprise ValueMkt cap + debt − cash | $16.5B | $206.8B |
| Trailing P/EPrice ÷ TTM EPS | 8.00x | 26.66x |
| Forward P/EPrice ÷ next-FY EPS est. | 10.97x | 19.04x |
| PEG RatioP/E ÷ EPS growth rate | — | 12.62x |
| EV / EBITDAEnterprise value multiple | 6.17x | 18.99x |
| Price / SalesMarket cap ÷ Revenue | 1.48x | 3.94x |
| Price / BookPrice ÷ Book value/share | 2.47x | 3.33x |
| Price / FCFMarket cap ÷ FCF | — | 27.93x |
SOLV leads this category, winning 5 of 5 comparable metrics.
Profitability & Efficiency
SOLV leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
SOLV delivers a 30.7% return on equity — every $100 of shareholder capital generates $31 in annual profit, vs $13 for TMO. TMO carries lower financial leverage with a 0.76x debt-to-equity ratio, signaling a more conservative balance sheet compared to SOLV's 1.00x.
| Metric | SOLVSolventum Corpora… | TMOThermo Fisher Sci… |
|---|---|---|
| ROE (TTM)Return on equity | +30.7% | +13.2% |
| ROA (TTM)Return on assets | +10.0% | +6.4% |
| ROICReturn on invested capital | +16.9% | +7.5% |
| ROCEReturn on capital employed | +19.0% | +9.1% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 |
| Debt / EquityFinancial leverage | 1.00x | 0.76x |
| Net DebtTotal debt minus cash | $4.2B | $31.0B |
| Cash & Equiv.Liquid assets | $878M | $9.9B |
| Total DebtShort + long-term debt | $5.0B | $40.9B |
| Interest CoverageEBIT ÷ Interest expense | 6.55x | 5.89x |
SOLV leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — SOLV and TMO each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TMO five years ago would be worth $10,211 today (with dividends reinvested), compared to $8,875 for SOLV. Over the past 12 months, TMO leads with a +16.6% total return vs SOLV's +8.5%. The 3-year compound annual growth rate (CAGR) favors SOLV at -3.9% vs TMO's -4.2% — a key indicator of consistent wealth creation.
| Metric | SOLVSolventum Corpora… | TMOThermo Fisher Sci… |
|---|---|---|
| YTD ReturnYear-to-date | -10.1% | -20.1% |
| 1-Year ReturnPast 12 months | +8.5% | +16.6% |
| 3-Year ReturnCumulative with dividends | -11.2% | -11.9% |
| 5-Year ReturnCumulative with dividends | -11.2% | +2.1% |
| 10-Year ReturnCumulative with dividends | -11.2% | +229.1% |
| CAGR (3Y)Annualised 3-year return | -3.9% | -4.2% |
Evenly matched — SOLV and TMO each lead in 3 of 6 comparable metrics.
Risk & Volatility
SOLV leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SOLV is the less volatile stock with a 1.05 beta — it tends to amplify market swings less than TMO's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SOLV currently trades 80.5% from its 52-week high vs TMO's 73.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SOLVSolventum Corpora… | TMOThermo Fisher Sci… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.05x | 1.10x |
| 52-Week HighHighest price in past year | $88.20 | $643.99 |
| 52-Week LowLowest price in past year | $62.38 | $385.46 |
| % of 52W HighCurrent price vs 52-week peak | +80.5% | +73.4% |
| RSI (14)Momentum oscillator 0–100 | 54.6 | 39.8 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 1.9M |
SOLV leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SOLV as "Buy" and TMO as "Buy". Consensus price targets imply 38.4% upside for TMO (target: $655) vs 37.7% for SOLV (target: $98). TMO is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.
| Metric | SOLVSolventum Corpora… | TMOThermo Fisher Sci… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $97.80 | $654.67 |
| # AnalystsCovering analysts | 11 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 8 |
| Dividend / ShareAnnual DPS | — | $1.69 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% |
Insufficient data to determine a leader in this category.
Key Takeaway
SOLV leads in 3 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 2 categories are tied.
Best OverallSolventum Corporation (SOLV)Leads 3 of 6 categories
Loading custom metrics...
SOLV vs TMO: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is SOLV or TMO a better buy right now?
For growth investors, Thermo Fisher Scientific Inc.
(TMO) is the stronger pick with 3. 9% revenue growth year-over-year, versus 0. 9% for Solventum Corporation (SOLV). Solventum Corporation (SOLV) offers the better valuation at 8. 0x trailing P/E (11. 0x forward), making it the more compelling value choice. Analysts rate Solventum Corporation (SOLV) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SOLV or TMO?
On trailing P/E, Solventum Corporation (SOLV) is the cheapest at 8.
0x versus Thermo Fisher Scientific Inc. at 26. 7x. On forward P/E, Solventum Corporation is actually cheaper at 11. 0x.
03Which is the better long-term investment — SOLV or TMO?
Over the past 5 years, Thermo Fisher Scientific Inc.
(TMO) delivered a total return of +2. 1%, compared to -11. 2% for Solventum Corporation (SOLV). Over 10 years, the gap is even starker: TMO returned +229. 1% versus SOLV's -11. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SOLV or TMO?
By beta (market sensitivity over 5 years), Solventum Corporation (SOLV) is the lower-risk stock at 1.
05β versus Thermo Fisher Scientific Inc. 's 1. 10β — meaning TMO is approximately 4% more volatile than SOLV relative to the S&P 500. On balance sheet safety, Thermo Fisher Scientific Inc. (TMO) carries a lower debt/equity ratio of 76% versus 100% for Solventum Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — SOLV or TMO?
By revenue growth (latest reported year), Thermo Fisher Scientific Inc.
(TMO) is pulling ahead at 3. 9% versus 0. 9% for Solventum Corporation (SOLV). On earnings-per-share growth, the picture is similar: Solventum Corporation grew EPS 221. 7% year-over-year, compared to 7. 3% for Thermo Fisher Scientific Inc.. Over a 3-year CAGR, SOLV leads at 0. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SOLV or TMO?
Solventum Corporation (SOLV) is the more profitable company, earning 18.
7% net margin versus 15. 1% for Thermo Fisher Scientific Inc. — meaning it keeps 18. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SOLV leads at 26. 2% versus 18. 2% for TMO. At the gross margin level — before operating expenses — SOLV leads at 53. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SOLV or TMO more undervalued right now?
On forward earnings alone, Solventum Corporation (SOLV) trades at 11.
0x forward P/E versus 19. 0x for Thermo Fisher Scientific Inc. — 8. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMO: 38. 4% to $654. 67.
08Which pays a better dividend — SOLV or TMO?
In this comparison, TMO (0.
4% yield) pays a dividend. SOLV does not pay a meaningful dividend and should not be held primarily for income.
09Is SOLV or TMO better for a retirement portfolio?
For long-horizon retirement investors, Thermo Fisher Scientific Inc.
(TMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10), +229. 1% 10Y return). Both have compounded well over 10 years (TMO: +229. 1%, SOLV: -11. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SOLV and TMO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SOLV is a mid-cap deep-value stock; TMO is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(SOLV: -3.0% · TMO: 6.2%)Net Margin>
%
(SOLV: 17.3% · TMO: 15.2%)P/E Ratio<
x
(SOLV: 8.0x · TMO: 26.7x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.